PDCD1 and melanoma: To study the response of elderly patients to treatment with PD-1 inhibitors, the group of 82 patients aged 65–79 years was defined as group A and the group of 62 patients aged 80–100 years was defined as group B. The investigators noted a trend toward higher ORR in group B compared with group A (73.9% vs. 62.3%) and a significantly higher CR rate in group B than in group A (47.9% vs. 20%), meaning that older melanoma patients over 80 years of age benefited the most.